OTCMKTS:MKGAY Merck KGaA (MKGAY) Stock Price, News & Analysis → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free MKGAY Stock Alerts $38.36 0.00 (0.00%) (As of 08/1/2017) Add Compare Share Share Today's Range$38.36▼$38.3650-Day Range$38.36▼$38.3652-Week Range$32.53▼$42.02VolumeN/AAverage Volume6,872 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Merck KGaA alerts: Email Address Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Merck KGaA Stock (OTCMKTS:MKGAY)Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate and Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility. The Life Science sector provides scientists with laboratory materials, technologies, and services. The Performance Materials sector offers specialty chemicals and materials for demanding applications. The firm offers pharma and biopharma manufacturing, pharmaceutical research, pharma quality control, and government and academic research services. The company was founded by Friedrich Jacob Merck in 1668 and is headquartered in Darmstadt, Germany.Read More MKGAY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MKGAY Stock News HeadlinesMay 1, 2024 | msn.comMerck Keytruda combo meets main goal in late-stage trial for advanced gastric cancerApril 19, 2024 | morningstar.comMerck KGaA MRKMay 5, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…March 19, 2024 | msn.comMerck Highlights Data From Multiple Phase 3 Trials For Its Investigational Pneumococcal Conjugate VaccineFebruary 8, 2024 | finanznachrichten.deFuture Scientists in the Making: MilliporeSigma's Curiosity Cube Wraps Up 2023 Multi-Country STEM TourJanuary 22, 2024 | wsj.comMerck KGaAJanuary 3, 2024 | morningstar.comMerck KGaA ADR MRKCNovember 9, 2023 | markets.businessinsider.comMerck KGaA Q3 Results Down; Now Sees FY23 Earnings In Lower Half Of Estimate RangeMay 5, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…October 22, 2023 | msn.comHow This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 StocksOctober 17, 2023 | msn.comFDA grants expanded approval for Merck's lung cancer drug KeytrudaOctober 16, 2023 | markets.businessinsider.comEC Approves Merck's KEYTRUDA As Adjuvant Treatment For Non-Small Cell Lung CancerOctober 10, 2023 | msn.comMerck's Lead Cancer Drug Meets Primary Goal In Certain Type Of Lung Cancer PatientsSeptember 28, 2023 | reuters.comMerck's blood vessel disorder therapy receives US FDA's priority reviewSeptember 25, 2023 | msn.comMerck and ICR enter renewed cancer drug discovery partnershipSeptember 20, 2023 | markets.businessinsider.comExscientia, Merck KGaA To Discover Drug Candidates Across Oncology, Neuroinflammation & ImmunologyAugust 3, 2023 | msn.comMerck KGaA reports Q2 resultsAugust 3, 2023 | markets.businessinsider.comMerck KGaA Q2 Results Down, Cuts FY23 View; Backs FY25 OutlookAugust 1, 2023 | finance.yahoo.comGlobal Cell and Gene Therapy Manufacturing Services Market to 2028, Led by Catalent, Lonza, Merck KGaA, and Thermo Fisher ScientificJuly 27, 2023 | benzinga.comMerck Releases Encouraging Data From Two Late-Stage Studies For Pneumococcal Conjugate VaccineJuly 27, 2023 | msn.comModerna/Merck begin late-stage study of mRNA cancer vaccineMay 1, 2023 | msn.comBarclays Maintains Merck (MRK) Overweight RecommendationApril 27, 2023 | msn.comMerck Makes a Bold Move That Could Transform Its BusinessApril 27, 2023 | washingtonpost.comMerck: Q1 Earnings SnapshotApril 27, 2023 | msn.comMerck Gains on Q1 BeatApril 26, 2023 | msn.comMerck Keeps Striking Out on Expanding Its Cancer-Drug JuggernautApril 12, 2023 | wsj.comMerck KGaA Shares Fall After US Puts Hold on New Patients in MS Drug TrialSee More Headlines Receive MKGAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merck KGaA and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceuticals - Major Sub-IndustryN/A Current SymbolOTCMKTS:MKGAY CUSIPN/A CIKN/A WebN/A Phone496151720FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesBelén Garijo LópezChairman-Executive Board & CEOMarcus KuhnertChief Financial OfficerLaura MatzChief Science & Technology OfficerDanny Bar-ZoharHead-Research & DevelopmentMeeta GulyaniEVP, Head-Strategy & Business DevelopmentKey CompetitorsAcacia Pharma GroupOTCMKTS:ACPGFECO Animal Health GroupOTCMKTS:EAHGF180 Life SciencesNASDAQ:ATNFW1933 IndustriesOTCMKTS:TGIFF3SBioOTCMKTS:TRSBFView All Competitors MKGAY Stock Analysis - Frequently Asked Questions Should I buy or sell Merck KGaA stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Merck KGaA in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MKGAY shares. View MKGAY analyst ratings or view top-rated stocks. How have MKGAY shares performed in 2024? Merck KGaA's stock was trading at $38.36 at the beginning of 2024. Since then, MKGAY stock has increased by 0.0% and is now trading at $38.36. View the best growth stocks for 2024 here. How do I buy shares of Merck KGaA? Shares of MKGAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:MKGAY) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyThe asset beating inflation by 4xColonial MetalsAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe only AI company you should be looking atBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merck KGaA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
